Myriad Genetics's Earnings Outlook

Myriad Genetics MYGN unveils its next round of earnings this Monday, May 03. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Net Income, Earnings, And Earnings Per Share

Earnings and especially earnings per share (EPS) are useful measures of a company's profitability. Total earnings, which is also referred to as net income, equals total revenue minus total expenses. EPS equals to net income divided by the number of shares outstanding.

Earnings And Revenue

Based on Myriad Genetics management projections, analysts predict EPS of $0.14 on revenue of $156.20 million. In the same quarter last year, Myriad Genetics announced EPS of $0.08 on revenue of $164.00 million.

What Are Analyst Estimates And Earnings Surprises, And Why Do They Matter?

Analysts who cover this company will publish forward-looking estimates of its revenue and EPS each quarter. Averaging together every EPS and revenue prediction that each analyst makes about a company in a quarter yields the "consensus estimates." A company posting earnings or revenue above or below the consensus estimate is known as an "earnings surprise" and may move the stock by a considerable margin.

If the company were to post earnings in line with the consensus estimate when it reports Monday, EPS would be down 75.0%. Revenue would be down 4.76% from the same quarter last year. Here is how the company's reported EPS has stacked up against analyst estimates in the past:

Stock Performance

Shares of Myriad Genetics were trading at $30.23 as of April 29. Over the last 52-week period, shares are up 96.92%. Given that these returns are generally positive, long-term shareholders should be content going into this earnings release.

Do not be surprised to see the stock move on comments made during its conference call. Myriad Genetics is scheduled to hold the call at 11:00:00 ET and can be accessed here.